Laia Josa-Culleré

Dr. Laia Josa-Culleré

MCS, Laboratory of Medicinal Chemistry & Synthesis, Department of Biological Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26, 08034 Barcelona, Spain
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2020 in ChemPhotoChem
Verified
Journal Article
Closed access
PDF file
Laia Josa-CulleréLaia Josa-Culleré
Laia Josa-Culleré
ALAmadeu Llebaria
Amadeu Llebaria

19 January 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
Laia Josa-CulleréLaia Josa-Culleré
Laia Josa-Culleré
ALAmadeu Llebaría
Amadeu Llebaría
The lack of selectivity of anticancer drugs limits current chemotherapy. Light-activatable drugs, whose activity can be precisely controlled with external light, could provide a more localized action of the drugs in the tumor, thus decreasing side effects and increasing efficacy. Herein, we introduce a series of photoswitchable azobenzene histone deacetylase inhibitors (HDACis) whose activity can be controlled by external visible light. Initial HDACis isomerized under ultraviolet light and were up to >50-fold more active under illumination than in the dark in enzyme assays. These were then optimized toward compounds responding to more permeable and less harmful green light by introducing o-halogen atoms into the azobenzene. Selected compounds decreased cell viability only under illumination in four different cancer cell lines. Overall, we present photoswitchable HDACis with optimized activation wavelengths, which inhibit enzyme activity and cell viability only upon illumination with visible light, contributing to the still limited toolbox of photoswitchable anticancer drugs.

14 October 2014 in RSC Advances
Verified
Journal Article
Open access
PDF file
Laia Josa-CulleréLaia Josa-Culleré
Laia Josa-Culleré
YWYelena A. Wainman
Yelena A. Wainman
KBKevin M. Brindle
Kevin M. Brindle
FLFinian J. Leeper
Finian J. Leeper
Diazoacetyl groups have been shown to undergo spontaneous cycloaddition reactions with strained alkenes and alkynes. The rates of reaction are similar to the equivalent reactions of azide groups. This allows diazo groups to be used as bioorthogonal reporter groups. This is demonstrated by fluorescent labelling of a diazoacetylated protein and of cell-surface glycans via metabolic incorporation of a diazoacetylated sugar.

26 February 2019 in Catalysts
Verified
Journal Article
Open access
PDF file
Laia Josa-CulleréLaia Josa-Culleré
Laia Josa-Culleré
ALAntti S. K. Lahdenperä
Antti S. K. Lahdenperä
ARAubert Ribaucourt
Aubert Ribaucourt
GHGeorg T. Höfler
Georg T. Höfler
SGSerena Gargiulo
Serena Gargiulo
CPCaroline E. Paul
Caroline E. Paul
Redox reactions catalyzed by highly selective nicotinamide-dependent oxidoreductases are rising to prominence in industry. The cost of nicotinamide adenine dinucleotide coenzymes has led to the use of well-established elaborate regeneration systems and more recently alternative synthetic biomimetic cofactors. These biomimetics are highly attractive to use with ketoreductases for asymmetric catalysis. In this work, we show that the commonly studied cofactor analogue 1-benzyl-1,4-dihydronicotinamide (BNAH) can be used with alcohol dehydrogenases (ADHs) under certain conditions. First, we carried out the rhodium-catalyzed recycling of BNAH with horse liver ADH (HLADH), observing enantioenriched product only with unpurified enzyme. Then, a series of cell-free extracts and purified ketoreductases were screened with BNAH. The use of unpurified enzyme led to product formation, whereas upon dialysis or further purification no product was observed. Several other biomimetics were screened with various ADHs and showed no or very low activity, but also no inhibition. BNAH as a hydride source was shown to directly reduce nicotinamide adenine dinucleotide (NAD) to NADH. A formate dehydrogenase could also mediate the reduction of NAD from BNAH. BNAH was established to show no or very low activity with ADHs and could be used as a hydride donor to recycle NADH.

4 June 2018 in Organic Letters
Verified
Journal Article
Closed access
SBSandra Balcells
Sandra Balcells
MHMaxwell B. Haughey
Maxwell B. Haughey
JWJohannes C. L. Walker
Johannes C. L. Walker
Laia Josa-CulleréLaia Josa-Culleré
Laia Josa-Culleré
CTChristopher Towers
Christopher Towers
TDTim Donohoe
Tim Donohoe

18 December 2017 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
Laia Josa-CulleréLaia Josa-Culleré
Laia Josa-Culleré
CTChristopher Towers
Christopher Towers
ATAmber L. Thompson
Amber L. Thompson
MMMark Moloney
Mark Moloney